Overview

A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.

Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double Blind, Placebo Controlled, Phase 2 Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple I.V. Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic Brain Injury.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott Products
Collaborator:
Quintiles, Inc.